Recent advances in the therapy of renal cancer

被引：7

作者：

Sonpavde, Guru ^{[1
]}

Hutson, Thomas E. ^{[1
]}

机构：

[1] Texas Oncol PA, Baylor Sammons Canc Ctr, Genitourinary Oncol Program, Dallas, TX 75246 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 02期

关键词：

metastatic renal cell cancer; monoclonal antibody; mTOR inhibitor; receptor tyrosine kinase inhibitor;

D O I：

10.1517/14712598.7.2.233

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Metastatic clear cell renal cell cancer has traditionally been treated with cytokines (interferon or interleukin-2). Improved understanding of biology has engendered novel targeted therapeutic agents that have radically altered the outlook. Vascular endothelial growth factor, the related receptor and the mTOR signal transduction pathway have particularly been exploited. Sunitinib malate, sorafenib and temsirolimus have improved clinical outcomes compared with interferon in randomized trials. Other multitargeted tyrosine kinase inhibitors (lapatinib, axatinib and pazopanib) and antiangiogenic agents (bevacizumab and lenalidomide) have also demonstrated activity in early studies. Combinations of these agents are being evaluated. The future of the therapy of renal cancer appears promising owing to the efficacy of these novel agents. Clinical trials designed to further assess these and other agents need to be vigorously supported.

引用

页码：233 / 242

页数：10

共 67 条

[1] Role of Raf in vascular protection from distinct apoptotic stimuli [J].

Alavi, A ;

Hood, JD ;

Frausto, R ;

Stupack, DG ;

Cheresh, DA .

SCIENCE, 2003, 301 (5629) :94-96

[2]

[Anonymous], J CLIN ONCOL

[3] Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer [J].

Atkins, M ;

Regan, M ;

McDermott, D ;

Mier, J ;

Stanbridge, E ;

Youmans, A ;

Febbo, P ;

Upton, M ;

Lechpammer, M ;

Signoretti, S .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3714-3721

[4] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[5]

Azad NS, 2006, J CLIN ONCOL, V24, p121S

[6]

Beer TM, 2006, J CLIN ONCOL, V24, p221S

[7] A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma [J].

Bleumer, I ;

Oosterwijk, E ;

Oosterwijk-Wakka, JC ;

Völler, MCW ;

Melchior, S ;

Warnaar, SO ;

Mala, C ;

Beck, J ;

Mulders, PFA .

JOURNAL OF UROLOGY, 2006, 175 (01) :57-62

[8] A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients [J].

Bleumer, I ;

Knuth, A ;

Oosterwijk, E ;

Hofmann, R ;

Varga, Z ;

Lamers, C ;

Kruit, W ;

Melchior, S ;

Mala, C ;

Ullrich, S ;

De Mulder, P ;

Mulders, PFA ;

Becks, J .

BRITISH JOURNAL OF CANCER, 2004, 90 (05) :985-990

[9]

Bui MHT, 2003, CLIN CANCER RES, V9, P802

[10]

BUKOWSKI RM, 2006, J CLIN ONCOL, V24

← 1 2 3 4 5 6 7 →